Bone Marrow-derived Mesenchymal Stem Cell Therapy in Retinitis Pigmentosa.

Nil Irem Ucgun, Cenk Zeki Fikret, Mualla Sahin Hamurcu
{"title":"Bone Marrow-derived Mesenchymal Stem Cell Therapy in Retinitis Pigmentosa.","authors":"Nil Irem Ucgun, Cenk Zeki Fikret, Mualla Sahin Hamurcu","doi":"10.2174/011574888X293265240311120103","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>To determine the effectiveness of bone marrow-derived mesenchymal stem cell therapy on visual acuity and visual field in patients with retinitis pigmentosa.</p><p><strong>Objective: </strong>Stem cell treatment in retinitis pigmentosa provides improvement in visual acuity and visual field.</p><p><strong>Method: </strong>Forty-seven eyes of 27 patients diagnosed with retinitis pigmentosa were included in our study. Allogeneic bone marrow-derived mesenchymal stem cells were administered by deep subtenon injection. Complete routine ophthalmological examinations, optical coherence tomography (Zeiss, Cirrus HD-OCT) measurements, and visual field (Humphrey perimetry, 30-2) tests were performed on all patients before the treatment and on the 1st, 3rd, and 6th month after treatment. The best corrected visual acuities of the patients were determined by the Snellen chart and converted to logMAR. Visual evoked potential (VEP) and electroretinogram (ERG) examinations of the patients before the treatment and on the 6th month after the treatment were performed (Metrovision) data were compared.</p><p><strong>Results: </strong>Visual acuities were 0.74 ± 0.49 logMAR before treatment and 0.61 ± 0.46 logMAR after treatment. Visual acuity had a statistically significant increase (p < 0.001). The visual field deviation was found to be -27.16 ± 5.77 dB before treatment and -26.59 ± 5.96 dB after treatment (p = 0.005). The ganglion cell layer was 46.26 ± 12.87 μm before treatment and 52.47 ± 12.26 μm after treatment (p = 0.003). There was a significant improvement in Pattern VEP 120º P100 amplitude compared to that before the treatment (4.43 ± 2.42 μV) and that after the treatment (5.09 ± 2.86 μV) (p = 0.013). ERG latency measurements were 18.33 ± 15.39 μV before treatment and 20.87 ± 18.64 μV after treatment for scotopic 0.01 (p = 0.02). ERG latency measurements for scotopic 3.0 were 20.75 ± 26.31 μV before treatment and 23.10 ± 28.60 μV after treatment (p = 0.014).</p><p><strong>Conclusion: </strong>Retinitis pigmentosa is a progressive, inherited disease that can result in severe vision loss. In retinitis pigmentosa, the application of bone marrow-derived mesenchymal stem cells by deep subtenon injection has positive effects on visual function. No systemic or ophthalmic side effects were detected in the patients during the 6-month follow-up period.</p>","PeriodicalId":93971,"journal":{"name":"Current stem cell research & therapy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current stem cell research & therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/011574888X293265240311120103","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: To determine the effectiveness of bone marrow-derived mesenchymal stem cell therapy on visual acuity and visual field in patients with retinitis pigmentosa.

Objective: Stem cell treatment in retinitis pigmentosa provides improvement in visual acuity and visual field.

Method: Forty-seven eyes of 27 patients diagnosed with retinitis pigmentosa were included in our study. Allogeneic bone marrow-derived mesenchymal stem cells were administered by deep subtenon injection. Complete routine ophthalmological examinations, optical coherence tomography (Zeiss, Cirrus HD-OCT) measurements, and visual field (Humphrey perimetry, 30-2) tests were performed on all patients before the treatment and on the 1st, 3rd, and 6th month after treatment. The best corrected visual acuities of the patients were determined by the Snellen chart and converted to logMAR. Visual evoked potential (VEP) and electroretinogram (ERG) examinations of the patients before the treatment and on the 6th month after the treatment were performed (Metrovision) data were compared.

Results: Visual acuities were 0.74 ± 0.49 logMAR before treatment and 0.61 ± 0.46 logMAR after treatment. Visual acuity had a statistically significant increase (p < 0.001). The visual field deviation was found to be -27.16 ± 5.77 dB before treatment and -26.59 ± 5.96 dB after treatment (p = 0.005). The ganglion cell layer was 46.26 ± 12.87 μm before treatment and 52.47 ± 12.26 μm after treatment (p = 0.003). There was a significant improvement in Pattern VEP 120º P100 amplitude compared to that before the treatment (4.43 ± 2.42 μV) and that after the treatment (5.09 ± 2.86 μV) (p = 0.013). ERG latency measurements were 18.33 ± 15.39 μV before treatment and 20.87 ± 18.64 μV after treatment for scotopic 0.01 (p = 0.02). ERG latency measurements for scotopic 3.0 were 20.75 ± 26.31 μV before treatment and 23.10 ± 28.60 μV after treatment (p = 0.014).

Conclusion: Retinitis pigmentosa is a progressive, inherited disease that can result in severe vision loss. In retinitis pigmentosa, the application of bone marrow-derived mesenchymal stem cells by deep subtenon injection has positive effects on visual function. No systemic or ophthalmic side effects were detected in the patients during the 6-month follow-up period.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
骨髓间充质干细胞疗法治疗视网膜色素变性。
背景:研究骨髓间充质干细胞疗法对视网膜色素变性患者视力和视野的影响:目的:确定骨髓间充质干细胞疗法对视网膜色素变性患者视力和视野的影响:干细胞治疗视网膜色素变性可改善视力和视野:我们的研究纳入了27名视网膜色素变性患者的47只眼睛。异体骨髓间充质干细胞通过腱膜下深部注射给药。在治疗前、治疗后第1、3和6个月,对所有患者进行了全面的常规眼科检查、光学相干断层扫描(蔡司,Cirrus HD-OCT)测量和视野(汉弗莱视力计,30-2)测试。患者的最佳矫正视力由斯奈伦视力表确定,并转换为对数分辨力。对治疗前和治疗后第 6 个月的患者进行视觉诱发电位(VEP)和视网膜电图(ERG)检查(Metrovision),并对数据进行比较:治疗前的视力为 0.74 ± 0.49 logMAR,治疗后为 0.61 ± 0.46 logMAR。在统计学上,视力有显著提高(p < 0.001)。治疗前的视野偏差为 -27.16 ± 5.77 dB,治疗后为 -26.59 ± 5.96 dB(p = 0.005)。神经节细胞层在治疗前为 46.26 ± 12.87 μm,治疗后为 52.47 ± 12.26 μm(p = 0.003)。与治疗前(4.43 ± 2.42 μV)和治疗后(5.09 ± 2.86 μV)相比,模式 VEP 120º P100 波幅有明显改善(p = 0.013)。治疗前的ERG潜伏期测量值为18.33 ± 15.39 μV,治疗后的ERG潜伏期测量值为20.87 ± 18.64 μV(散光0.01)(p = 0.02)。散光 3.0 的 ERG 潜伏期测量结果为:治疗前 20.75 ± 26.31 μV,治疗后 23.10 ± 28.60 μV(p = 0.014):视网膜色素变性是一种渐进性遗传疾病,可导致严重的视力丧失。结论:视网膜色素变性症是一种渐进性遗传疾病,可导致严重的视力丧失。在视网膜色素变性症中,通过腱膜下深部注射骨髓间充质干细胞对视功能有积极影响。在6个月的随访期间,未发现患者出现全身或眼部副作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Effect of miR-98/IL-6/STAT3 on Autophagy and Apoptosis of Cardiac Stem Cells Under Hypoxic Conditions In vitro. Human Umbilical Cord Mesenchymal Stem Cell-derived Exosome Regulates Intestinal Type 2 Immunity. Kartogenin Induces Chondrogenesis in Cartilage Progenitor Cells and Attenuates Cell Hypertrophy in Marrow-Derived Stromal Cells. The Mechanisms of Mesenchymal Stem Cells in the Treatment of Experimental Autoimmune Encephalomyelitis. The Role of Stem Cell Therapies in the Treatment of Neurodegenerative Diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1